

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited an⦠read more
Healthcare
Medical Care Facilities
5 years
USD
Exclusive to Premium users
$5.45
Price-2.51%
-$0.14
$523.211m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$138.555m
+10.7%
1y CAGR-16.6%
3y CAGR-19.3%
5y CAGR-$1.61
+30.0%
1y CAGR+7.8%
3y CAGR+0.7%
5y CAGR$162.555m
$293.536m
Assets$130.981m
Liabilities$35.288m
Debt12.0%
-0.2x
Debt to EBITDA-$148.288m
-24.4%
1y CAGR-12.9%
3y CAGR-23.6%
5y CAGR